The future of AI regulation in drug development: a comparative analysis

Area of Science:

• Regulatory Science
• Artificial Intelligence in Drug Development
• Pharmaceutical Policy

Background:

• Artificial intelligence (AI) is increasingly integral to pharmaceutical research and development.
• Existing regulatory frameworks are adapting to accommodate AI-driven advancements in drug discovery and clinical trials.
• Key agencies, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are developing distinct approaches to AI oversight.

Purpose of the Study:

• To conduct a comparative analysis of the FDA's and EMA's regulatory responses to AI in drug development.
• To propose a framework for understanding regulatory divergence between the US and EU.
• To assess the maturity of AI applications for standardized regulation within evolving policy landscapes.

Main Methods:

• Comparative analysis of regulatory documents, executive orders, and legislation (e.g., EU AI Act).
• Development of an analytical framework to contrast the FDA's dialog-driven model with the EMA's risk-tiered approach.
• Examination of AI applications across drug development stages: target identification, generative chemistry, and clinical trial digital twins.

Main Results:

• The FDA employs a flexible, individualized assessment model, fostering innovation but potentially creating uncertainty.
• The EMA utilizes a structured, risk-tiered approach, offering predictability but possibly slowing early adoption.
• Convergence on risk-based principles is observed, yet significant transatlantic implementation differences persist, influenced by US policy shifts and reduced international cooperation.

Conclusions:

• Regulatory uncertainty in the US, contrasted with more stable European rules, presents both opportunities and challenges for AI in drug development.
• Divergent regulatory philosophies impact the pace and predictability of AI innovation in the pharmaceutical sector.
• Harmonization efforts are needed to navigate transatlantic differences and foster global AI-driven drug development.